Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Nevirapine vs Viramune in HIV-1 Patients
NCT02202005Phase 1Completed
- Sponsor
- Ratiopharm
- Start
- Aug 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nevirapine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Ratiopharm. Primary endpoints: Area Under the Concentration Time Curve at Steady State at Day 56, Concentration at the End of Dosing Interval at Steady State at Day 56 and 1 more. Started Aug 2014; status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02202005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202005.